Background: Fingolimod (FTY) is the first oral medication approved for multiple sclerosis therapy. Until now, little has been known about the effects of FTY withdrawal regarding disease activity and development of tumefactive demyelinating lesions (TDLs), as already described in patients who discontinue natalizumab. Methods: In this study we present the clinical and radiological findings of two patients who had a severe rebound after FTY withdrawal and compare these with patients identified by a PubMed data bank analysis using the search term 'fingolimod rebound'. In total, 10 patients, of whom three developed TDLs, are presented. Results: Patients suffering from TDLs were free of clinical and radiological signs of disease activity under FTY therapy (100% versus 57%, compared with patients without TDLs) and had rebounds after a mean of 14.6 weeks (standard deviation 11.5) [patients without TDLs 11.7 (standard deviation 3.4)]. Conclusion: We propose that a good therapeutic response to FTY might be predisposing for a severe rebound after withdrawal. Consequently, therapy switches should be planned carefully with a short therapy free interval.
Case series
The sphingosine-1-phosphate receptor modulator, fingolimod (FTY), was the first oral medication approved for treatment of relapsing remitting (RR) multiple sclerosis (MS) [Lucchinetti et al. 2008] . FTY reduces the annual relapse rate (ARR) by about 50% [Calabresi et al. 2014] and is approved in the European Union for treatment of highly active RRMS. As rebounds of disease activity are described in RRMS patients after withdrawal of highly effective drugs -especially after natalizumab (Nat) discontinuation [Sorensen et al. 2014] , the question arises whether MS rebounds might also occur after FTY discontinuation and whether these cases share similarities which may be helpful to identify patients at risk for a rebound after FTY withdrawal.
We present two cases with severe MS rebounds including TDLs after FTY withdrawal and compare these with eight other published cases found using the search term 'fingolimod rebound' in the PubMed database (seven publications). Tumefactive demyelinating lesions (TDLs) are over 0.2 cm in size in T2-weighted and FLAIR magnetic resonance imaging (MRI) sequences hyperintense lesions. They are characterized by ring enhancement with gadolinium and resemble either an abscess or a tumor. Yet there is no clear definition criteria for TDLs [Ernst et al. 1998; Dastgir and Dimario, 2009 ]. In the natural course of the disease, patients with initial TDLs and lesion size >5 cm rather exhibit a 'normal disease course of MS' on follow up or even better with disease duration >10 years, as objectified by the Expanded Disability Status Scale (EDSS) [Lucchinetti et al. 2008] .
First, we present the case of a 44-year-old Caucasian woman. MS was diagnosed in 2008 (age of onset: 38 years) and interferon (IFN) β1a intramuscular (i.m.) therapy was initiated. Due to intolerable muscle cramps and a worsening of gait ataxia, IFN-β1a was withdrawn in October 2012. After a therapyfree interval of 2 weeks, FTY was initiated in November 2012. During FTY treatment, the patient was free of clinical and radiological signs of disease activity (MRI May 2013, Figure 1a ). Nevertheless, due to four documented episodes of lymphopenia with a minimum lymphocyte count of 70 per µl in October 2013 (range 70-370 per µl), therapy was withdrawn in December 2013 and switched to dimethyl fumarate (DMF) 2 × 120 mg in February 2014. The patient was admitted to our hospital 2 months later with paresthesia and worsening of the paresis of the right leg (EDSS 5.0). White blood cell counts showed 6500 per µl leukocytes with 1180 per µl lymphocytes (18.9%). MRI (March 2014) revealed new contrast enhancing lesions right parietal (2.3 cm × 2.2 cm × 2.9cm), left paraventricular and in the pontine area ( Figure  1 ). Investigation of cerebrospinal fluid (CSF) for JC virus copies was negative. Intravenous (i.v.) methylprednisolone treatment (1000 mg for 5 days) combined with two intrathecal triamcinolone injections (2 × 60mg) led to a marked improvement of clinical symptoms (EDSS 4.5 in June 2014, EDSS 4.0 in September 2014) and MRI findings (Figure 1c , f, i: April 2014 and September 2014). DMF treatment was continued.
The second patient was a 36-year-old female with a disease course of 13 years. She had not been relapse free during treatment with subcutaneous (s.c.) IFNβ (IFN-β1b s.c. 250 µg every second day; IFN-β1a s.c. 3 × 22µg and 44µg) and glatiramer acetate therapy; thus Nat was initiated in September 2010. During the following 2 years (24 Nat infusions, September 2010 to September 2012), she had been free of RRMS disease activity. Due to a severe bronchitis (September 2012), classified as possible adverse event of Nat, the medication was withdrawn. After a therapy-free interval of 6 months, FTY was started in March 2013. No relapses occurred during FTY therapy. On 23 December 2013, she was admitted to hospital because of angina pectoris and FTY was stopped immediately. DMF 2 × 120 mg was started 7 weeks later; 1 week later she developed a cognitive decline, ataxia, disturbed balance and difficulties with writing and coordination. Cranial MRI performed at the beginning of March 2014 showed multiple contrast enhancing lesions, one of them in the right cerebellum involving the middle cerebellar peduncle (Figure 2 a, c, e). At this time point the lymphocyte count was 1392 per µl (18.3%, 7610 leucocytes per µl). She was treated with i.v. methylprednisolone (1000 mg, 3 days), leading to complete remission.
Discussion
As previously described in Nat patients [Jander et al. 2012] , switching from a potent and effective treatment regimen might cause a severe MS rebound after FTY withdrawal. The release of lymphocytes after withdrawal of FTY with rapid influx of lymphocytes into the CSF and reconstitution of the immune system has been discussed as reason for MS rebound [Havla et al. 2012 ]. Additionally, whereas B cells in the periphery are strongly reduced they are untouched in the CSF upon treatment with FTY [Kowarik et al. 2011 ]. Furthermore, in patients suffering from rebounds after switching therapy differential diagnoses such as neuromyelitis optica (NMO) or NMO spectrum have to be discussed. Up to now there have been no predictive factors defining this risk group. Of note, in both cases patients were on DMF during the diagnosis of TDLs; however, assumptions concerning the efficacy of fumarates in these cases are difficult objectify about as one patient was on treatment for only 1 week. Nevertheless, the treatment did not seem to be strong and fast enough to maintain disease stability. Experience with fumarates is still scarce and thus the possibility that TDLs developed due to this treatment regimen or that it favored the development of TDLs cannot be discarded.
TDLs are challenging as no specific treatment guidelines exist [Siffrin et al. 2014] . Comparing these two patients with cases mentioned in PubMed articles demonstrates that three patients had TDLs whereas seven had a 'nontumefactive' rebound (Tables 1 and 2). Patients In patients with TDLs the rebounds occurred after 14.6 (SD 11.5) weeks post-cessation of FTY therapy versus 11.7 (SD 3.4). Thus, it has to be stated that 70% of the patients with rebound after FTY withdrawal were free of clinical and radiological disease activity during FTY therapy and the reasons for FTY withdrawal were side effects in 60%.
Therefore, a beneficial therapeutic response to FTY therapy might be a predisposing factor for severe MS rebound after withdrawal, due to a return of previous high disease activity. Consequently, especially in this patient population with beneficial FTY therapy response and intolerable side effects, switching to an alternative immunotherapy should be performed carefully. Sometimes dosing of patients every other day might be a treatment option. Thus, the need for a therapy-free interval should be critically weighed against the risk of an MS rebound.
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